Klier Jörg, König Frank, Johannsen Manfred, Eichenauer Rolf, Schönfelder Robert, Schröder Jörg, Hempel Elke, Doehn Christian
Urologische Partnerschaft Köln (UPK), Köln, Germany.
Urologie, ATURO, Berlin, Germany.
Aktuelle Urol. 2023 Jun;54(3):196-201. doi: 10.1055/a-2063-3196. Epub 2023 May 24.
At the beginning of 2017, the German Society of Uro-Oncologists (d-uo) had the idea of designing a documentation platform that would enable d-uo members to report cancer cases to the cancer registry and transfer data to d-uo's own database - without a double effort. The cancer registry reimburses the first notification of a tumour with €18. As the only provider, d-uo reimburses its members for the documentation effort associated with the additional notification to d-uo with a further €18. In addition to the basic oncological data set, further parameters were defined by d-uo. This data is collected, evaluated and interpreted as part of the VERSUS study. At the end of 2022, 14,834 patients with a newly diagnosed urological tumour were included in the VERSUS study. Almost two thirds of all patients had prostate cancer. About half of all patients with prostate cancer were diagnosed as part of an early detection measure. These patients then also had more favourable tumour stages. Overall, almost every eighth patient already had metastases at the time of initial diagnosis. Data from the VERSUS study are available for 2,167 operations on prostate cancer with tumour category T2 or T3. There were 1,360 operations in patients with a T2 tumour (62.8%) and 807 operations in patients with T3 tumours (37.2%). A positive margin was present in 25.5% of all operated-on patients. In relation to tumour categories T2 and T3, the proportion of a positive resection margin was 14.3% and 44.2%, respectively. The VERSUS study will continue to provide answers to many questions from the uro-oncological field with reference to the "real world" situation in Germany.
2017年初，德国泌尿肿瘤学家协会（d-uo）提出设计一个文档平台的想法，该平台将使d-uo成员能够向癌症登记处报告癌症病例，并将数据传输到d-uo自己的数据库，而无需重复劳动。癌症登记处为首次报告肿瘤支付18欧元。作为唯一的提供者，d-uo为其成员因向d-uo额外报告而产生的文档工作再报销18欧元。除了基本的肿瘤学数据集外，d-uo还定义了其他参数。这些数据作为VERSUS研究的一部分进行收集、评估和解读。到2022年底，VERSUS研究纳入了14834例新诊断的泌尿肿瘤患者。所有患者中近三分之二患有前列腺癌。所有前列腺癌患者中约有一半是在早期检测措施中被诊断出来的。这些患者的肿瘤分期也更有利。总体而言，几乎每八名患者在初次诊断时就已经有转移。VERSUS研究的数据可用于2167例肿瘤类别为T2或T3的前列腺癌手术。T2肿瘤患者有1360例手术（62.8%），T3肿瘤患者有807例手术（37.2%）。所有接受手术的患者中有25.5%切缘阳性。就肿瘤类别T2和T3而言，切缘阳性的比例分别为14.3%和44.2%。VERSUS研究将继续针对德国“现实世界”的情况，回答泌尿肿瘤领域的许多问题。
